Premium
Variability in clinical decision‐making for ventricular assist device implantation in pediatrics
Author(s) -
Joong Anna,
Gossett Jeffrey G.,
Blume Elizabeth D.,
Thrush Philip,
Pahl Elfriede,
Mongé Michael C.,
Backer Carl L.,
Patel Angira
Publication year - 2020
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/petr.13840
Subject(s) - medicine , candidacy , ventricular assist device , clinical decision making , pediatrics , emergency medicine , intensive care medicine , heart failure , politics , political science , law
Background Minimal data exist on clinical decision‐making in VAD implantation in pediatrics. This study aims to identify areas of consensus/variability among pediatric VAD physicians in determining eligibility and factors that guide decision‐making. Methods An 88‐item survey with clinical vignettes was sent to 132 pediatric HT cardiologists and surgeons at 37 centers. Summary statistics are presented for the variables assessed. Results Total respondents were 65 (72% cardiologists, 28% surgeons) whose centers implanted 1‐5 (34%), 6‐10 (40%), or >10 (26%) VADs in the past year. Consensus varied by patients’ age, diagnosis, and Pedimacs profile. Highest agreement to offer VAD (97%) was a mechanically ventilated teenager with dilated cardiomyopathy. Patients stable on inotropes were less likely offered VAD (11%‐25%). SV infant with Pedimacs profile 2 had the most varied responses: 37% offered VAD; estimated survival ranged from 15% to 90%. Variables considered for VAD eligibility included mild developmental delays (100% offered VAD), moderate‐severe behavioral concerns (46%), cancer in remission >2 years (100%), active malignancy with good prognosis (68%) or uncertain prognosis (36%), and BMI >35 (74%) or <15 (69%). Most respondents (91%) would consider destination therapy VADs in pediatrics, though not currently feasible at 1/3 of centers. Factors with greatest influence on decision‐making included HT candidacy, families’ goals of care, and risks of complications. Conclusions Significant variation exists among pediatric VAD physicians when determining VAD eligibility and estimating survival, which can lead to differences in access to emerging technologies across institutions. Further work is needed to understand and mitigate these differences.